The potential utility of phage therapy in the treatment of periprosthetic infection caused by multidrug-resistant pathogens: a review

封面


如何引用文章

全文:

详细

Background. One of the main and most costly problems in large joint arthroplasty associated with socially significant losses is periprosthetic infection. Of particular importance is periprosthetic joint infection (PJI) caused by antibiotic-resistant pathogens and followed by the worst treatment results. Currently, when antibiotic-resistant pathogens are spreading rapidly, particularly in health facilities, researchers are constantly looking for alternative treatments for severe cases of PJI. Phage therapy can be one of these methods.

The aim of the review was to analyse the application of personalized bacteriophages in the management of periprosthetic infection caused by multidrug-resistant pathogens during arthroplasty of large joints of the lower extremities.

Methods. A 20-year literature search (2003-2023) was performed in the eLIBRARY, PubMed, Google Scholar, and Scopus electronic databases.

Results. During the search, 1.482 publications meeting the objectives of this review were found. Taking into account the inclusion/non-inclusion criteria adopted by the authors, the review included 12 studies describing 45 cases of the use of bacteriophages in the management of hip and knee PJI caused by multidrug-resistant pathogens. The infection was eradicated without recurrence in 42 cases (89.4%), recurrence was recorded only in 5 cases (10.6%).

Conclusions. The analysis of the literature confirms that a combination therapy of personalized phages and antibiotics as adjuvant therapy is safe and effective. Bacteriophage treatment is a promising direction in the fight against resistant pathogens of periprosthetic infection. Its combination with antibiotics seems to be the most promising, as it can significantly increase the effectiveness of therapy for infections caused by multidrug-resistant pathogens due to the synergy of these drug classes.

作者简介

Taalaibek Sheraliev

Tsivyan Novosibirsk Research Institute of Traumatology and Orthopaedics

编辑信件的主要联系方式.
Email: sheraliev.taalai@mail.ru
ORCID iD: 0000-0002-7261-2730
SPIN 代码: 8092-9687
俄罗斯联邦, Novosibirsk

Alexander Samokhin

Tsivyan Novosibirsk Research Institute of Traumatology and Orthopaedics

Email: motorist@inbox.ru
ORCID iD: 0000-0001-5599-3925

Cand. Sci. (Med.)

俄罗斯联邦, Novosibirsk

Baikozho Tashtanov

Tsivyan Novosibirsk Research Institute of Traumatology and Orthopaedics

Email: b.tashtanov95@gmail.com
ORCID iD: 0000-0002-8553-9712
俄罗斯联邦, Novosibirsk

Andrey Korytkin

Tsivyan Novosibirsk Research Institute of Traumatology and Orthopaedics

Email: andrey.korytkin@gmail.com
ORCID iD: 0000-0001-9231-5891

Cand. Sci. (Med.)

俄罗斯联邦, Novosibirsk

Vitaliy Pavlov

Tsivyan Novosibirsk Research Institute of Traumatology and Orthopaedics

Email: pavlovdoc@mail.ru
ORCID iD: 0000-0002-8997-7330

Dr. Sci. (Med.)

俄罗斯联邦, Novosibirsk

参考

  1. Шералиев Т.У., Федоров Е.А., Гольник В.Н., Павлов В.В. Перипротезная инфекция при эндопротезировании тазобедренного сустава: особенности современной этиологии, проблемы и перспективы диагностики: монография. Красноярск: Научно-инновационный центр; 2021. 230 c. doi: 10.12731/978-5-907208-50-6. Sheraliev T.U., Fedorov E.A., Golnik V.N., Pavlov V.V. Periprosthetic infection during hip replacement: features of modern etiology, problems and diagnostic prospects: monograph. Krasnoyarsk: Scientific and Innovation Center; 2021. 230 p. (In Russian). doi: 10.12731/978-5-907208-50-6.
  2. Asokan G.V., Ramadhan T., Ahmed E., Sanad H. WHO Global Priority Pathogens List: A Bibliometric Analysis of Medline-PubMed for Knowledge Mobilization to Infection Prevention and Control Practices in Bahrain. Oman Med J. 2019;34(3):184-193. doi: 10.5001/omj.2019.37.
  3. Козлов Р.С., Голуб А.В. Остановить темпы роста антибиотикорезистентности микроорганизмов сегодня — дать шанс на выживание человечества завтра. Клиническая микробиология и антимикробная химиотерапия. 2019;21(4):310-315. doi: 10.36488/cmac.2019.4.310-315. Kozlov R.S., Golub A.V. To stop the progress of antimicrobial resistance today means to give a chance of mankind surviving tomorrow. Clinical Microbiology and Antimicrobial Chemotherapy. 2019;21(4):310-315. (In Russian). doi: 10.36488/cmac.2019.4.310-315.
  4. Darwich A., Dally F.J., Abu Olba K., Mohs E., Gravius S., Hetjens S. et al. Superinfection with Difficult-to-Treat Pathogens Significantly Reduces the Outcome of Periprosthetic Joint Infections. Antibiotics (Basel). 2021;10(10):1145. doi: 10.3390/antibiotics10101145.
  5. Wimmer M.D., Hischebeth G.T.R., Randau T.M., Gathen M., Schildberg F.A., Fröschen F.S. et al. Difficult-to-treat pathogens significantly reduce infection resolution in periprosthetic joint infections. Diagn Microbiol Infect Dis. 2020;98(2):115114. doi: 10.1016/j.diagmicrobio.2020.115114.
  6. Винклер Т., Трампуш А., Ренц Н., Перка К., Божкова С.А. Классификация и алгоритм диагностики и лечения перипротезной инфекции тазобедренного сустава. Травматология и ортопедия России. 2016;22(1):33-45. (In Russian). doi: 10.21823/2311-2905-2016-0-1-33-45. Winkler T., Trampuz A., Renz N., Perka C., Bozhkova S.A. Classification and algorithm for diagnosis and treatment of hip prosthetic joint infection. Traumatology and Orthopedics of Russia. 2016;22(1):33-45. (In Russian). doi: 10.21823/2311-2905-2016-0-1-33-45.
  7. Ливенцов В.Н., Божкова C.А., Кочиш А.Ю., Артюх В.А., Разоренов В.Л., Лабутин Д.В. Трудноизлечимая перипротезная инфекция тазобедренного сустава: результаты санирующих операций. Травматология и ортопедия России. 2019;25(4): 88-97. doi: 10.21823/2311-2905-2019-25-4-88-97. Liventsov V.N., Bozhkova S.A., Kochish A.Yu., Artyukh V.A., Razorenov V.L., Labutin D.V. Difficult-To-Treat Periprosthetic Hip Infection: Outcomes of Debridment. Traumatology and Orthopedics of Russia. 2019;25(4):88-97. (In Russian). doi: 10.21823/2311-2905-2019-25-4-88-97.
  8. Ferry T., Kolenda C., Batailler C., Gustave C.A., Lustig S., Malatray M. et al. Phage Therapy as Adjuvant to Conservative Surgery and Antibiotics to Salvage Patients With Relapsing S. aureus Prosthetic Knee Infection. Front Med (Lausanne). 2020;7:570572. doi: 10.3389/fmed.2020.570572.
  9. Cano E.J., Caflisch K.M., Bollyky P.L., Van Belleghem J.D., Patel R., Fackler J. et al. Phage Therapy for Limb-threatening Prosthetic Knee Klebsiella pneumoniae Infection: Case Report and In Vitro Characterization of Anti-biofilm Activity. Clin Infect Dis. 2021;73(1):e144-e151. doi: 10.1093/cid/ciaa705.
  10. Doub J.B, Johnson A.J., Nandi S., Ng V., Manson T., Lee M. et al. Experience Using Adjuvant Bacteriophage Therapy for the Treatment of 10 Recalcitrant Periprosthetic Joint Infections: A Case Series. Clin Infect Dis. 2023;76(3):e1463-e1466. doi: 10.1093/cid/ciac694.
  11. Kovacs C.J., Rapp E.M., McKenzie S.M., Mazur M.Z., Mchale R.P., Brasko B. et al. Disruption of Biofilm by Bacteriophages in Clinically Relevant Settings. Mil Med. 2023:189(5-6):е1294-е1302. doi: 10.1093/milmed/usad385.
  12. Ландышев Н.Н., Воронько Я.Г., Тимошина О.Ю., Суслина С.Н., Акимкин В.Г., Мирошников К.А. Обзор законодательства в области обращения персонализированных препаратов бактериофагов. Вопросы вирусологии. 2020;65(5):259-266. doi: 10.36233/0507-4088-2020-65-5-2. Landyshev N.N., Voronko Ya.G., Timoshina O.Yu., Suslina S.N., Akimkin V.G., Miroshnikov K.A. A review of the regulatory framework for personalized bacteriophages registration. Problems of Virology. 2020;65(5):259-266. (In Russian). doi: 10.36233/0507-4088-2020-65-5-2.
  13. Tkhilaishvili T., Winkler T., Müller M., Perka C., Trampuz A. Bacteriophages as Adjuvant to Antibiotics for the Treatment of Periprosthetic Joint Infection Caused by Multidrug-Resistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2019;64(1):e00924-19. doi: 10.1128/AAC.00924-19.
  14. Ferry T., Batailler C., Petitjean C., Chateau J., Fevre C., Forestier E. et al. The Potential Innovative Use of Bacteriophages Within the DAC® Hydrogel to Treat Patients With Knee Megaprosthesis Infection Requiring “Debridement Antibiotics and Implant Retention” and Soft Tissue Coverage as Salvage Therapy. Front Med (Lausanne). 2020;7:342. doi: 10.3389/fmed.2020.00342.
  15. Cesta N., Pini M., Mulas T., Materazzi A., Ippolito E., Wagemans J. et al. Application of Phage Therapy in a Case of a Chronic Hip-Prosthetic Joint Infection due to Pseudomonas aeruginosa: An Italian Real-Life Experience and In Vitro Analysis. Open Forum Infect Dis. 2023;10(2):ofad051. doi: 10.1093/ofid/ofad051.
  16. Ferry T., Kolenda C., Batailler C., Gaillard R., Gustave C.A., Lustig S. et al. Case Report: Arthroscopic “Debridement Antibiotics and Implant Retention” With Local Injection of Personalized Phage Therapy to Salvage a Relapsing Pseudomonas Aeruginosa Prosthetic Knee Infection. Front Med (Lausanne). 2021;8: 569159. doi: 10.3389/fmed.2021.569159.
  17. Ferry T., Leboucher G., Fevre C., Herry Y., Conrad A., Josse J. et al. Salvage Debridement, Antibiotics and Implant Retention («DAIR») With Local Injection of a Selected Cocktail of Bacteriophages: Is It an Option for an Elderly Patient With Relapsing Staphylococcus aureus Prosthetic-Joint Infection? Open Forum Infect Dis. 2018;5(11):ofy269. doi: 10.1093/ofid/ofy269.
  18. Neuts A.S., Berkhout H.J., Hartog A., Goosen J.H.M. Bacteriophage therapy cures a recurrent Enterococcus faecalis infected total hip arthroplasty? A case report. Acta Orthop. 2021;92(6):678-680. doi: 10.1080/17453674.2021.1968714.
  19. Schoeffel J., Wang E.W., Gill D., Frackler J., Horne B., Manson T. et al. Successful Use of Salvage Bacteriophage Therapy for a Recalcitrant MRSA Knee and Hip Prosthetic Joint Infection. Pharmaceuticals (Basel). 2022; 15(2):177. doi: 10.3390/ph15020177.
  20. Ramirez-Sanchez C., Gonzales F., Buckley M., Biswas B., Henry M., Deschenes M.V. et al. Successful Treatment of Staphylococcus aureus Prosthetic Joint Infection with Bacteriophage Therapy. Viruses. 2021;13(6):1182. doi: 10.3390/v13061182.
  21. Fedorov E., Samokhin A., Kozlova Y., Kretien S., Sheraliev T., Morozova V. et al. Short-Term Outcomes of Phage-Antibiotic Combination Treatment in Adult Patients with Periprosthetic Hip Joint Infection. Viruses. 2023;15(2):499. doi: 10.3390/v15020499.
  22. Clarke A.L., De Soir S., Jones J.D. The Safety and Efficacy of Phage Therapy for Bone and Joint Infections: A Systematic Review. Antibiotics (Basel). 2020;9(11):795. doi: 10.3390/antibiotics9110795.
  23. Лыско К.А., Отрашевская Е.В., Игнатьев Г.М. Лечебно-профилактические препараты бактериофагов: краткий обзор производства и применения. БИОпрепараты. Профилактика, диагностика, лечение. 2013;(4):4-9. Lysko K.A., Otrashevskaya E.V., Ignatyev G.M. Curative and preventive bacteriophage drugs: short review of manufacturing and use. Biological Products. Prevention, Diagnosis, Treatment. 2013;(4):4-9. (In Russian).
  24. Wang L., Di Luca M., Tkhilaishvili T., Trampuz A., Gonzalez Moreno M. Synergistic Activity of Fosfomycin, Ciprofloxacin, and Gentamicin Against Escherichia coli and Pseudomonas aeruginosa Biofilms. Front Microbiol. 2019;10:2522. doi: 10.3389/fmicb.2019.02522.
  25. Pirnay J.P., Verbeken G., Ceyssens P.J., Huys I., De Vos D., Ameloot C. et al. The Magistral Phage. Viruses. 2018;10(2):64. doi: 10.3390/v10020064.
  26. Suh G.A., Lodise T.P., Tamma P.D., Knisely J.M., Alexander J., Aslam S. et al. Considerations for the Use of Phage Therapy in Clinical Practice. Antimicrob Agents Chemother. 2022;66(3):e0207121. doi: 10.1128/AAC.02071-21.
  27. Patey O., McCallin S., Mazure H., Liddle M., Smithyman A., Dublanchet A. Clinical Indications and Compassionate Use of Phage Therapy: Personal Experience and Literature Review with a Focus on Osteoarticular Infections. Viruses. 2018;11(1):18. doi: 10.3390/v11010018.
  28. Ly-Chatain M.H. The factors affecting effectiveness of treatment in phages therapy. Front Microbiol. 2014;5:51. doi: 10.3389/fmicb.2014.00051.
  29. Chan B.K., Sistrom M., Wertz J.E., Kortright K.E., Narayan D., Turner P.E. Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa. Sci Rep. 2016;6:26717. doi: 10.1038/srep26717.
  30. Gu Liu C., Green S.I., Min L., Clark J.R., Salazar K.C., Terwilliger A.L. et al. Phage-Antibiotic Synergy Is Driven by a Unique Combination of Antibacterial Mechanism of Action and Stoichiometry. mBio. 2020;11(4): e01462-20. doi: 10.1128/mBio.01462-20.
  31. Racenis K., Rezevska D., Madelane M., Lavrinovics E., Djebara S., Petersons A. et al. Use of Phage Cocktail BFC 1.10 in Combination With Ceftazidime-Avibactam in the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Femur Osteomyelitis-A Case Report. Front Med (Lausanne). 2022;9:851310. doi: 10.3389/fmed.2022.851310.
  32. Doub J.B., Chan B., Johnson A.J. Salphage: Salvage bacteriophage therapy for a chronic Enterococcus faecalis prosthetic joint infection. IDCases. 2023;33:e01854. doi: 10.1016/j.idcr.2023.e01854.
  33. Mah T.F., O’Toole G.A. Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol. 2001; 9(1):34-39. doi: 10.1016/s0966-842x(00)01913-2.
  34. Гордина Е.М., Божкова С.А. Бактериальные биопленки в ортопедии: проблема и возможные перспективы профилактики. РМЖ. 2021;8:29-32. Gordina E.M., Bozhkova S.A. Bacterial biofilms in orthopedics: the problem and possible prospects for prevention. RMJ. 2021;8:29-32. (In Russian).
  35. Akanda Z.Z., Taha M., Abdelbary H. Current review-The rise of bacteriophage as a unique therapeutic platform in treating peri-prosthetic joint infections. J Orthop Res. 2018;36(4):1051-1060. doi: 10.1002/jor.23755.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Eco-Vector, 2024

Creative Commons License
此作品已接受知识共享署名-非商业性使用-禁止演绎 4.0国际许可协议的许可。
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 82474 от 10.12.2021.


##common.cookie##